A detailed history of Td Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Td Asset Management Inc holds 522,205 shares of VRTX stock, worth $270 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
522,205
Previous 504,054 3.6%
Holding current value
$270 Million
Previous $236 Million 2.8%
% of portfolio
0.23%
Previous 0.23%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$460.0 - $505.78 $8.35 Million - $9.18 Million
18,151 Added 3.6%
522,205 $243 Million
Q2 2024

Aug 02, 2024

SELL
$392.81 - $485.53 $4.46 Million - $5.51 Million
-11,346 Reduced 2.2%
504,054 $236 Million
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $7.55 Million - $8.26 Million
-18,513 Reduced 3.47%
515,400 $215 Million
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $18.5 Million - $22.1 Million
53,850 Added 11.22%
533,913 $217 Million
Q3 2023

Oct 27, 2023

BUY
$338.18 - $362.46 $34.9 Million - $37.4 Million
103,097 Added 27.35%
480,063 $167 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $3.02 Million - $3.39 Million
-9,620 Reduced 2.49%
376,966 $133 Million
Q1 2023

May 10, 2023

BUY
$283.23 - $323.1 $1.86 Million - $2.12 Million
6,572 Added 1.73%
386,586 $122 Million
Q4 2022

Feb 06, 2023

SELL
$285.76 - $321.48 $17 Million - $19.2 Million
-59,581 Reduced 13.55%
380,014 $110 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $532,873 - $594,561
-1,946 Reduced 0.44%
439,595 $129 Million
Q2 2022

Aug 04, 2022

BUY
$234.96 - $292.55 $1.17 Million - $1.46 Million
4,975 Added 1.14%
441,541 $124 Million
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $23.6 Million - $27.9 Million
106,787 Added 32.38%
436,566 $114 Million
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $1.74 Million - $2.2 Million
9,855 Added 3.08%
329,779 $72.4 Million
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $4.66 Million - $5.21 Million
-25,689 Reduced 7.43%
319,924 $58 Million
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $25.1 Million - $29.6 Million
-134,074 Reduced 27.95%
345,613 $69.7 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $25.4 Million - $29.6 Million
-122,706 Reduced 20.37%
479,687 $103 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $3.8 Million - $5.07 Million
-18,348 Reduced 2.96%
602,393 $142 Million
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $7.36 Million - $8.72 Million
28,773 Added 4.86%
620,741 $169 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $2.51 Million - $3.29 Million
11,139 Added 1.92%
591,968 $172 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $4.46 Million - $5.54 Million
22,345 Added 4.0%
580,829 $138 Million
Q4 2019

Feb 11, 2020

SELL
$166.71 - $223.91 $1.75 Million - $2.35 Million
-10,495 Reduced 1.84%
558,484 $122 Million
Q3 2019

Nov 07, 2019

BUY
$166.23 - $187.09 $5.3 Million - $5.97 Million
31,902 Added 5.94%
568,979 $96.4 Million
Q2 2019

Aug 01, 2019

BUY
$164.61 - $190.37 $2.95 Million - $3.41 Million
17,903 Added 3.45%
537,077 $98.5 Million
Q1 2019

May 08, 2019

BUY
$163.73 - $194.7 $2.75 Million - $3.26 Million
16,768 Added 3.34%
519,174 $95.5 Million
Q4 2018

Feb 01, 2019

BUY
$151.91 - $192.21 $1.55 Million - $1.96 Million
10,202 Added 2.07%
502,406 $83.3 Million
Q3 2018

Nov 01, 2018

BUY
$167.73 - $192.74 $5.87 Million - $6.74 Million
34,971 Added 7.65%
492,204 $94.9 Million
Q2 2018

Jul 31, 2018

SELL
$145.72 - $169.96 $6.41 Million - $7.48 Million
-44,008 Reduced 8.78%
457,233 $77.7 Million
Q1 2018

May 11, 2018

BUY
$151.6 - $177.13 $1.95 Million - $2.28 Million
12,868 Added 2.63%
501,241 $81.7 Million
Q4 2017

Feb 02, 2018

BUY
$137.28 - $155.55 $4.96 Million - $5.62 Million
36,133 Added 7.99%
488,373 $73.2 Million
Q3 2017

Nov 09, 2017

BUY
$148.13 - $162.24 $67 Million - $73.4 Million
452,240
452,240 $68.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.